Status and phase
Conditions
Treatments
About
Alopecia areata (AA) is an auto immune disorder. Treatment of severe types remains difficult with a rate of hair regrowth which is lower than 10%. This RCT will assess the safety and efficacy of methotrexate alone or associated with low doses of prednisone versus placebo in the treatment of severe types of AA.
Full description
Background: Alopecia areata (AA) is an auto immune disorder. Chronic and severe types of AA have a major impact on patients' quality of life. Treatment of severe types of AA include phototherapy, pulse IV corticosteroids, topical immunotherapy. These treatments are poorly effective in severe types of AA, since the rate of hair regrowth remains lower than 10%. Methotrexate is an immunosuppressant which is used in many autoimmune skin disorders.
Aim: To assess the safety and efficacy of methotrexate versus placebo in the treatment of severe types of AA.
Design: Patients will be randomly assigned to receive methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after 5 months will continue methotrexate or placebo from month 6 to the end of the study (month 12). Non responder patients will be re randomized to receive either methotrexate alone or associated with prednisone 0.3 mg/Kg/day from month 6 to the end of the study (month 12).
Study Design Primary outcome Rate of complete or almost complete hair regrowth at the month 12 evaluation in patients treated with methotrexate or placebo who have not been re randomized after the month 5 evaluation and have staid in their initial group of randomization Secondary outcomes
Arm description Arm A: methotrexate 20 to 25 mg / week for 6 months. Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).
Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):
Eligibility criteria Inclusion criteria
Non inclusion criteria
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Pregnant or breast feeding women
VIH + patients
active hepatitis B or C
treatment with immunosuppressant (ciclosporine, mycophénolate mofetil
, cyclophosphamide, azathioprine, méthotrexate) within 2 months before inclusion
severe cardiac arythma or severe cardiac insufficiency or severe coronary disease
liver disorder
alcool consumption
renal failure
Severe diabetes mellitus
past history of severe infection
past history of néoplasiae ( excluding BCC),
Karnofsky index <à 50 %
severe lung disorder
mental impairment
symptomatic osteoporosis
blood cytopénia (hémoglobine < 10 g/l ; leucocytes< 3000/mm3, platelets< 100 000/mm3)
albuminémia < 25 g/l
Primary purpose
Allocation
Interventional model
Masking
90 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal